🚀 VC round data is live in beta, check it out!
Strategic Partners Valuation Multiples
Discover revenue and EBITDA valuation multiples for Strategic Partners and similar public comparables like Opthea, Newbury Pharmaceuticals, Genetic Technologies, Geovax Labs and more.
Strategic Partners Overview
About Strategic Partners
Strategic Partners A/S formerly Orphazyme AS is a Danish company. The company enters into strategic partnerships with companies with planned potential, where it can take active ownership and create value through its competencies.
Founded
2009
HQ
Employees
1
Website
Sectors
Financials (FY)
EV
$2M
Strategic Partners Financials
Strategic Partners reported last fiscal year revenue of $49K and negative EBITDA of ($385K).
In the same fiscal year, Strategic Partners generated ($385K) in EBITDA losses and had net loss of ($135K).
Strategic Partners P&L
In the most recent fiscal year, Strategic Partners reported revenue of $49K and EBITDA of ($385K).
Strategic Partners expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $49K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($385K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (792%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (792%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($135K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (278%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Strategic Partners Stock Performance
Strategic Partners has current market cap of $4M, and enterprise value of $2M.
Market Cap Evolution
Strategic Partners' stock price is $101.69.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2M | $4M | 0.0% | XXX | XXX | XXX | $-3.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStrategic Partners Valuation Multiples
Strategic Partners trades at 34.8x EV/Revenue multiple, and (4.4x) EV/EBITDA.
Strategic Partners Financial Valuation Multiples
As of April 19, 2026, Strategic Partners has market cap of $4M and EV of $2M.
Equity research analysts estimate Strategic Partners' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Strategic Partners has a P/E ratio of (31.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV (current) | $2M | XXX | $2M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 34.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (4.4x) | XXX | XXX | XXX |
| P/E | — | XXX | (31.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Strategic Partners Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Strategic Partners Margins & Growth Rates
Strategic Partners' revenue in the last fiscal year grew by —.
Strategic Partners' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Strategic Partners Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (792%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 1117% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 145% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 892% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Strategic Partners Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Strategic Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| Newbury Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Genetic Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Geovax Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| JFL Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Strategic Partners M&A Activity
Strategic Partners acquired XXX companies to date.
Last acquisition by Strategic Partners was on XXXXXXXX, XXXXX. Strategic Partners acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Strategic Partners
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStrategic Partners Investment Activity
Strategic Partners invested in XXX companies to date.
Strategic Partners made its latest investment on XXXXXXXX, XXXXX. Strategic Partners invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Strategic Partners
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Strategic Partners
| When was Strategic Partners founded? | Strategic Partners was founded in 2009. |
| Where is Strategic Partners headquartered? | Strategic Partners is headquartered in Denmark. |
| How many employees does Strategic Partners have? | As of today, Strategic Partners has over 1 employees. |
| Is Strategic Partners publicly listed? | Yes, Strategic Partners is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Strategic Partners? | Strategic Partners trades under STRAP ticker. |
| When did Strategic Partners go public? | Strategic Partners went public in 2017. |
| Who are competitors of Strategic Partners? | Strategic Partners main competitors are Opthea, Newbury Pharmaceuticals, Genetic Technologies, Geovax Labs. |
| What is the current market cap of Strategic Partners? | Strategic Partners' current market cap is $4M. |
| What is the current revenue of Strategic Partners? | Strategic Partners' last fiscal year revenue is $49K. |
| What is the current EV/Revenue multiple of Strategic Partners? | Current revenue multiple of Strategic Partners is 34.8x. |
| Is Strategic Partners profitable? | No, Strategic Partners is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.